Investors in Neurocrine Biosciences, Inc. NBIX need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 19, 2025 $70.00 Call had some of the highest...
Explore the exciting world of Neurocrine Biosciences (NASDAQ: NBIX) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends...
Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences (NASDAQ: NBIX) hasn't been wowing analysts lately. On Monday, no less than three...
Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.
Investors in Neurocrine Biosciences, Inc. NBIX need to pay close attention to the stock based on moves in the options market lately. That is because the Nov. 15, 2024 $80.00 Call had some of the highest...
Motley Fool analysts Matt Argersinger and Yasser El-Shimy face off.
According to analysts, here are three top-notch mid-cap growth stocks to snag at a discount now.
The company promises to advance a top investigational drug to late-stage testing, but investors might not think that's a fine idea.